

# HPTN 071 (PopART)


## Population Effects of Antiretroviral Therapy to Reduce HIV Transmission

IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA:  
RESULTS OF A COMMUNITY-RANDOMIZED TRIAL

HPTN ANNUAL MEETING  
WASHINGTON DC: JUNE 2019

# Insufficient progress on prevention

*Number of new HIV infections, global, 1990–2017 and 2020 target*



Source: UNAIDS 2018 estimates.



## Two landmark studies show Viral suppression **PREVENTS** transmission

- HPTN052 HIV serodifferent couples reduced HIV transmission by 96%
- PARTNER study showed ZERO transmissions from people living with HIV with HIV viral load < 200 copies HIV RNA/ml



## Universal testing and treatment

- All community members should test regularly for HIV and know their status (*Universal testing*)
- All those diagnosed HIV-positive should be offered ART immediately (*Universal treatment*)
- Once established on ART and “virally suppressed”, risk of transmission to partners is negligible

Undetectable = Untransmissible

# Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model




Reuben M Granich, Charles F Gilks, Christopher Dye, Kevin M De Cock, Brian G Williams

## Summary

**Background** Roughly 3 million people worldwide were receiving antiretroviral therapy (ART) at the end of 2007, but an estimated 6·7 million were still in need of treatment and a further 2·7 million became infected with HIV in 2007. Prevention efforts might reduce HIV incidence but are unlikely to eliminate this disease. We investigated a theoretical strategy of universal voluntary HIV testing and immediate treatment with ART, and examined the conditions under which the HIV epidemic could be driven towards elimination.

Published Online  
November 26, 2008  
DOI:10.1016/S0140-6736(08)61697-9  
See Online/Comment  
DOI:10.1016/S0140-6736(08)61697-9







## PopART: What were the questions?

- Universal testing and treatment (UTT) proposed as strategy to achieve steep reductions in HIV incidence
- Can UTT be delivered in practice in generalized epidemics in sub-Saharan Africa?
- What impact on HIV incidence can actually be achieved?






**21 Communities**

**7 per arm (A, B & C)**




**12 in Zambia**



**9 in S Africa**

**Total population ~1M**

**Study  
Design**



Total estimated Population of all 21 study communities 1 million people



# Primary Outcome measurement

**2,500 random sample from each community  
(aged 18-44)**


***Population Cohort (N=52,500) PC***

**Followed up annually for 36 months**




## CHiPs Door-To-Door Intervention


- Universal HIV counselling and testing
- VMMC referral
- PMTCT referral
- STI screening
- TB screening
- Condoms



# Study Timeline



# Delivery of intervention: ART coverage in arm A & B communities at end of trial



# Baseline characteristics of Population Cohort (PC0)

	Arm A N = 12,671	Arm B N = 13,404	Arm C N = 12,399
Male	28%	29%	30%
Age: 18 – 24	40%	39%	40%
25 – 34	39%	39%	38%
35 – 44	21%	23%	22%
HIV Prevalence: Overall	21%	21%	22%
Men	12%	11%	12%
Women	25%	25%	27%
HSV2 Prevalence: Overall	44%	43%	46%
ART (self-reported coverage in HIV+)	33%	41%	35%
Viral suppression (HIV+; 75/community)	56%	57%	54%
Medical Male Circumcision	17%	16%	19%





## Primary outcome

- HIV incidence in Population Cohort
- Between PC12 and PC36 (pre-specified)
- Time of infection imputed for seroconverters who were not seen at PC12 and/or PC24
- Impact comparing Arm A vs C, and Arm B vs C
- Using methods for matched cluster-randomized trials



# HIV Incidence by community (PC12-PC36)



Triplets

- Z Triplet 1
- Z Triplet 2
- Z Triplet 3
- Z Triplet 4
- SA Triplet 5
- SA Triplet 6
- SA Triplet 7

Events

- 10
- 20
- 30
- 40



## Primary analysis: Incidence in PC12-PC36

	Arm A	Arm B	Arm C
HIV Incidence (geometric mean of community incidence rates)	198/12,990 (1.45%)	157/14,149 (1.06%)	198/12,563 (1.55%)
Adjusted Rate Ratio (95% CI)	0.93 (0.74, 1.18)	0.70 (0.55, 0.88)	1
Incidence compared to Arm C	7% reduction	30% reduction	
P value	0.51	0.006	

Adjusted for age category, sex and baseline community HIV prevalence.  
Reported numbers include imputation for PC12 and PC24 missed visits



## Viral suppression at PC24

	Arm A	Arm B	Arm C
Viral suppression (Geometric mean of community %)	1531/2159 (72%)	1318/1891 (68%)	1480/2183 (60%)
Adjusted prevalence ratio (95% CI)	1.16 (0.99, 1.36)	1.08 (0.92, 1.27)	1
VS compared to Arm C	16% increase	8% increase	
P value	0.07	0.30	

Adjusted for age category, sex.



## Hypotheses for Arm A vs C finding

- Poorer delivery of intervention in Arm A
- Written informed consent initially required to start ART outside local guidelines in Arm A
- Sexual risk disinhibition in Arm A if perceived risk lower
- Higher migration or mobility in Arm A communities leading to “contamination”
- Chance



## Post-hoc analysis of (A + B) vs C

- Note: Interventions in Arms A and B were identical for most of the primary analysis period
- Combining arms A and B, and comparing with Arm C;
  - **RR = 0.81 (95% CI: 0.66 – 0.99; p = 0.04)**

**Evidence of a ~20% reduction in HIV incidence**



# PopART and the other UTT trials

UTT trials reported previously:

- TasP (South Africa)
- SEARCH (Uganda and Kenya)
- BCPP (Botswana)



## ANRS 12249 TasP: HIV incidence comparison

	Number of HIV- positive DBS tests	Person- years	Incidence for 100 person-years	95% CI
Control	268	11,787	<b>2.27</b>	2.00-2.55
Intervention	227	10,646	<b>2.13</b>	1.85-2.41
<b>TOTAL</b>	495	22,434	2.21	2.01-2.40

### Adjusted risk ratio\*


	aRR	95% CI	P-value
Intervention vs control	0.95	0.79-1.14	0.5821

*\* Estimated with Poisson regression, adjusted on sex, age, change in national ART guidelines, baseline cluster HIV prevalence and ART coverage*


*Dabis et al, AIDS 2016, Durban*

# ANRS 12249 TasP - Estimated cascade of care

## UNAIDS target




## TasP trial (1<sup>st</sup> January 2016)



# Impact of SEARCH on Cumulative HIV incidence

## No difference detected



Among incidence cohort of baseline HIV-negative stable residents; 91% intervention, 91% control alive and not out-migrated by year 3; of those, 89% intervention and 90% control with HIV status measured at year 3

# Primary Results: HIV Incidence in the Intervention vs. Standard of Care Arms



**57 participants in the intervention arm (annualized HIV incidence: 0.59%) and 90 in the standard of care arm (annualized HIV incidence: 0.92%) acquired HIV.**

Results of unadjusted and adjusted analyses of treatment effect

Analysis	Incidence Ratio	95% CI	2-sided p-value
Primary analysis (permutation test, pair-specific Cox PHM), unadjusted	0.69		0.09
Analysis to obtain 95% CI (standard pair-stratified Cox PHM), unadjusted	0.65	0.46-0.90	0.01
Primary analysis, adjusted*	0.62		0.04
Analysis to obtain 95% CI, adjusted*	0.70	0.50-0.99	0.04

\* Covariates in adjusted analyses were: sex, age, education, marital status, concurrent sexual partners, and alcohol during last sex


**Results of main analyses are consistent, and indicate at least **30% reduction in HIV incidence** associated with the intervention**

## HPTN 071 (PopART): What have we shown?

- Feasible and acceptable to deliver community-wide HIV services in urban communities with severe HIV epidemics
- PopART achieved the UNAIDS 90-90-90 targets with overall Viral Suppression of around 70% - increased from ~55% at start of trial
- Over 3 years, *population-level* HIV incidence was around 20% *lower* in Arms A and B than in Arm C
- Proportions with *detectable* viral load (at 24m) were ~30% in Arms A/B and ~40% in Arm C –consistent with an expected effect on HIV transmission of ~20-25%

# HPTN 071 (PopART) and UTT trials

- Results of all four UTT trials are aligned with this paradigm:
- Effect on HIV transmission is consistent with the reduction in unsuppressed viral load comparing intervention and control arms
- This means that the product of the three 90s is a valuable marker for delivery of *treatment as prevention*






## HPTN 071 (PopART): What have we shown?


- A sustained annual reduction in incidence of 20% would have a profound impact on the incidence curve and move us towards the UNAIDS “ending AIDS” targets
- **Community-based services for *universal* HIV testing and linkage are a key component of combination prevention in the global effort to achieve effective HIV control.**

# ACKNOWLEDGEMENTS


- Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) under Cooperative Agreements # UM1 AI068619, UM1-AI068617, and UM1-AI068613
- Funded by:
  - The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)
  - The International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation
  - NIAID, the National Institute of Mental Health (NIMH), and the National Institute on Drug Abuse (NIDA) all part of the U.S. National Institutes of Health (NIH)



**LONDON SCHOOL of HYGIENE & TROPICAL MEDICINE**




**Imperial College London**




**HPTN**  
HIV Prevention  
Trials Network

**The HPTN 071 Study Team, led by:**


**Dr. Richard Hayes**  
**Dr. Sarah Fidler**  
**Dr. Helen Ayles**  
**Dr. Nulda Beyers**  
**Dr. Peter Bock**



**Zambart Project**



**DESMOND TUTU CENTRE - SENTRUM**  
Every breath counts



**Government Agencies:**





**CITY OF CAPE TOWN**  
ISIXEKO SASEKAPA  
STAD KAAPSTAD



**Western Cape Government**  
Health



**PEPFAR Implementing Partners:**



